Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

<p><strong>BACKGROUND:</strong> Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity of vaccines is often worse in...

Full description

Bibliographic Details
Main Authors:	Ramasamy, MN, Minassian, AM, Ewer, KJ, Flaxman, AL, Folegatti, PM, Owens, DR, Voysey, M, Aley, PK, Angus, B, Babbage, G, Belij-Rammerstorfer, S, Berry, L, Bibi, S, Bittaye, M, Cathie, K, Chappell, H, Charlton, S, Cicconi, P, Clutterbuck, EA, Colin-Jones, R, Dold, C, Emary, KRW, Fedosyuk, S, Fuskova, M, Gbesemete, D, Green, C, Hallis, B, Hou, MM, Jenkin, D, Joe, CCD, Kelly, EJ, Kerridge, S, Lawrie, AM, Lelliott, A, Lwin, MN, Makinson, R, Marchevsky, NG, Mujadidi, Y, Munro, APS, Pacurar, M, Plested, E, Rand, J, Rawlinson, T, Rhead, S, Robinson, H, Ritchie, AJ, Ross-Russell, AL, Saich, S, Singh, N, Pollard, AJ, Oxford COVID Vaccine Trial Group
Format:	Journal article
Language:	English
Published:	Elsevier 2020

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Similar Items